Few Insured Individuals Receive Timely Direct-Acting Antiviral Treatment for Hepatitis C
Few insured individuals with hepatitis C virus (HCV) infection receive timely direct-acting antiviral (DAA) treatment.
Few insured individuals with hepatitis C virus (HCV) infection receive timely direct-acting antiviral (DAA) treatment.
Percentage undergoing HCV screening test increased from 16.6 percent in quarter 1 of 2011 to 40.6 percent in quarter 2 of 2021
Researchers assessed the effectiveness of both sofosbuvir/velpatasvir and gelcaprevir/pibrentasvir among patients infected with hepatitis C genotype 6.
Researchers assessed the effect of preoperative antiviral treatment for hepatitis C virus on the risk for surgical-related complications in patients who underwent total joint arthroplasty.
A team of researchers analyzed the virologic response of hepatitis C virus to direct-acting antivirals in patients with HIV.
Researchers assessed the characteristics and distribution of hepatitis C virus (HCV) genotypes among individuals with confirmed HCV infection who donated blood during a 16-year period.
Researchers assessed whether the rate of treatment initiations for hepatitis C virus infection among patients participating in a methadone treatment program increased after the implementation of a hepatology clinic.
Researchers conducted a study to determine whether the addition of a default screening order in the electronic health record increases the rate of hepatitis C virus screening among hospitalized patients.
Investigators conducted a study to determine the effect of syringes with fixed needles vs those with detachable needles on the risk for hepatitis C virus transmission among people who use injectable drugs.
The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes.